DBV Technologies (NASDAQ:DBVT) Price Target Raised to $47.00

DBV Technologies (NASDAQ:DBVT) had its price target lifted by Citizens Jmp from $45.00 to $47.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

Several other analysts also recently commented on the company. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on DBV Technologies in a report on Thursday, December 18th. Guggenheim restated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.65.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $20.00 on Friday. The company has a 50-day simple moving average of $21.58 and a two-hundred day simple moving average of $17.33. The stock has a market capitalization of $1.11 billion, a PE ratio of -3.83 and a beta of -0.97. DBV Technologies has a 52-week low of $5.30 and a 52-week high of $26.18.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). The firm had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $1.06 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. As a group, equities research analysts forecast that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC boosted its holdings in shares of DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares during the last quarter. Allworth Financial LP bought a new stake in DBV Technologies during the fourth quarter valued at approximately $32,000. Royal Bank of Canada purchased a new stake in DBV Technologies during the fourth quarter valued at approximately $34,000. Finally, New York State Common Retirement Fund purchased a new stake in DBV Technologies during the third quarter valued at approximately $34,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.